Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.
Journal Information
Full Title: Onco Targets Ther
Abbreviation: Onco Targets Ther
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Disclosure CU reports consulting for Epizyme, AbbVie, Atara, Pharmacyclics, Gilead, Janssen, Beigene, Lilly, and Incyte. The authors report no other conflicts of interest in this work."
Funding Disclosure
Evidence found in paper:
"There is no funding to report."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025